Managing Dermatologic Complications in Oncology

News
Video

Diverse dermatologic AEs, such as hair and nail toxicities, can be associated with various cancer treatments.

Patients with cancer frequently experience a wide spectrum of dermatologic, hair, and nail changes, along with mucosal surface issues, as a direct consequence of their treatments. These adverse effects (AEs) observed are dependent upon the treatment administered and require qualified clinicians to understand and determine specific treatment options.

Jonathan Leventhal, MD, director of the residency program, director of the Onco-Dermatology Clinic, and associate professor term at Yale School of Medicine, spoke with CancerNetwork® about observed AEs and how he and his team go about diagnosing and treating them. Some observed effects include those on the hair, nails, and skin and can occur from received treatment such as targeted therapies or immunotherapies.

The advent of targeted therapies has introduced a new profile of dermatologic toxicities, including acneiform and hand-foot skin reaction. Furthermore, these agents can contribute to a predisposition for nail infections, a common and often painful complication. With the increasing use of immune checkpoint inhibitors, clinicians are encountering a unique set of dermatologic AEs. Additionally, radiation therapy, a cornerstone of cancer treatment, is well-known for inducing localized skin reactions such as radiation dermatitis.

Transcript:

Patients who are undergoing cancer treatment frequently have many issues that impact their skin, hair, nails, and mucosal surfaces. A lot depends on the type of treatment that they’re on. For instance, chemotherapy often results in hair loss; nail changes; multiple types of skin rashes, such as toxic erythema of chemotherapy; and mucositis. Patients who are on targeted therapies often have acne-type rashes or a hand-foot skin reaction and other issues that can impact their hair and nails. We see [many] nail infections. Patients on immune checkpoint inhibitor therapy can have a variety of rashes. These are often autoimmune in nature. They [experience] a lot of itching as well. Radiation can cause a lot of skin reactions, such as radiation dermatitis, among others. All types of cancer therapy can result in dermatologic complications.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
Related Content